These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 8973211)
1. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity. Qiu J; Catapano CV; Fernandes DJ Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211 [TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Chen M; Beck WT Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726 [TBL] [Abstract][Full Text] [Related]
3. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Kim R; Beck WT Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863 [TBL] [Abstract][Full Text] [Related]
4. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26. Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414 [TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Wolverton JS; Danks MK; Granzen B; Beck WT Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239 [TBL] [Abstract][Full Text] [Related]
6. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009 [TBL] [Abstract][Full Text] [Related]
7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
8. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Morgan SE; Cadena RS; Raimondi SC; Beck WT Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639 [TBL] [Abstract][Full Text] [Related]
9. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Wolverton JS; Danks MK; Schmidt CA; Beck WT Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902 [TBL] [Abstract][Full Text] [Related]
10. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687 [TBL] [Abstract][Full Text] [Related]
11. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479 [TBL] [Abstract][Full Text] [Related]
12. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line. Patel S; Austin CA; Fisher LM Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515 [TBL] [Abstract][Full Text] [Related]
13. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148 [TBL] [Abstract][Full Text] [Related]
14. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057 [TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase II isozymes involved in anticancer drug action and resistance. Fernandes DJ; Qiu J; Catapano CV Adv Enzyme Regul; 1995; 35():265-81. PubMed ID: 7572348 [TBL] [Abstract][Full Text] [Related]
16. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
18. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26. Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648 [TBL] [Abstract][Full Text] [Related]
19. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909 [TBL] [Abstract][Full Text] [Related]
20. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]